Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490022 | 0.85 | MAPT (0.50) | ALDH1A1MAPTPKMHPGDALOX15 | |
| SCHEMBL3848372 | 0.85 | MAPT (0.50) | ALDH1A1MAPTPKMHPGDALOX15 | |
| SCHEMBL21889820 | 0.82 | ERCC1 (0.53) | ALDH1A1MAPTHPGDALOX15HSD17B10 | |
| SCHEMBL577923 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTPKMHPGDALOX15 | |
| SCHEMBL31314863 | 0.75 | MAPT (0.50) | ALDH1A1MAPTPKMHPGDALOX15 | |
| SCHEMBL2330083 | 0.75 | MAPT (0.50) | ALDH1A1MAPTPKMHPGDALOX15 | |
| SCHEMBL11568728 | 0.74 | CASP3 (0.45) | ALDH1A1MAPTPKMHPGDALOX15 | |
| Pyridine SCHEMBL5081848 | 0.72 | HTT (0.46) | ALDH1A1MAPTPKMHPGDALOX15 | |
| SCHEMBL11748785 | 0.71 | ALDH1A1 (0.47) | ALDH1A1MAPTPKMHPGDALOX15 | |
| SCHEMBL3851030 | 0.71 | ALDH1A1 (0.47) | ALDH1A1MAPTPKMHPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590158-B2 | Total synthesis of shishijimicin A and analogs thereof | WILLIAM MARSH RICE UNIVERSITY (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180327439-A1 | TOTAL SYNTHESIS OF SHISHIJIMICIN A AND ANALOGS THEREOF | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-11-15 | — | — | US | disclosed |
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | BERGER MARKUS | 2008-07-10 | — | — | US | disclosed |
| US-7335775-B2 | Effector conjugates, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-02-26 | — | — | US | disclosed |
| US-20070088060-A1 | New effector conjugates, process for their production and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-04-19 | — | — | US | disclosed |
| US-7129254-B2 | Effector conjugates, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-31 | — | — | US | disclosed |
| EP-1524979-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | Schering AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050026971-A1 | New effector conjugates, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2005-02-03 | — | — | US | disclosed |
| WO-2004012735-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| EP-0793497-B1 | NOVEL ENEDIYNE QUINONE IMINES AND METHODS OF PREPARATION AND USE THEREOF | SLOAN KETTERING INST CANCER (US) | 2003-02-12 | — | — | EP | disclosed |
| EP-0793497-A4 | NOVEL ENEDIYNE QUINONE IMINES AND METHODS OF PREPARATION AND USE THEREOF | SLOAN KETTERING INST CANCER (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1997041109-A1 | SYNTHESIS OF (±) - CALICHEAMICINONE, PRECURSORS, INTERMEDIATES AND DERIVATIVES | UNIVERSITY OF ALBERTA (CA) | 1997-11-06 | — | — | WO | disclosed |
| EP-0793497-A1 | NOVEL ENEDIYNE QUINONE IMINES AND METHODS OF PREPARATION AND USE THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 1997-09-10 | — | — | EP | disclosed |
| US-5622958-A | ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1996016655-A1 | NOVEL ENEDIYNE QUINONE IMINES AND METHODS OF PREPARATION AND USE THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-06-06 | — | — | WO | disclosed |
| EP-0454494-B1 | Calicheamicinone, derivatives and analogs thereof and methods of making the same | UNIV YALE (US) | 1995-09-20 | — | — | EP | disclosed |
| US-5384412-A | 4-trihydrocarbylsiloxy-6-methyltetrahydropyran derivatives; anticarcinogenic agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-01-24 | — | — | US | disclosed |
| US-5264586-A | Antibiotics, antitumor, chemical intermediates | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-11-23 | — | — | US | disclosed |
| WO-1993001810-A1 | ANALOGS OF CALICHEAMICIN η1I, METHOD OF MAKING AND USING THE SAME | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0454494-A2 | Calicheamicinone, derivatives and analogs thereof and methods of making the same | YALE UNIVERSITY (US) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590158-B2 | Total synthesis of shishijimicin A and analogs thereof | SYK, UGT1A7, FCGRT | ALDH1A1 809/4885MAPT 1590/4885PKM 1289/4885 |
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | ALDH1A1 1845/4885MAPT 3760/4885PKM 3262/4885 |
| US-20180327439-A1 | TOTAL SYNTHESIS OF SHISHIJIMICIN A AND ANALOGS THEREOF | SYK, UGT1A7, FCGRT | ALDH1A1 809/4885MAPT 1590/4885PKM 1289/4885 |
| US-20050026971-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | ALDH1A1 1845/4885MAPT 3760/4885PKM 3262/4885 |
| US-20070088060-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | ALDH1A1 1845/4885MAPT 3760/4885PKM 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.